CMS wants Medicare drug-price negotiation locked into permanent rules

The Centers for Medicare & Medicaid Services published a proposed rule 12 June that would convert the Medicare Drug Price Negotiation Program from guidance-based implementation into a formal, permanent regulatory framework — with the public comment period on the proposal closing 17 August [s1].

What's actually changing here

Since the Inflation Reduction Act created Medicare's authority to negotiate drug prices directly with manufacturers, CMS has run the program largely through non-binding guidance documents rather than formal regulations. This proposed rule, designated CMS-4215-P, would replace that approach with codified rules governing drug selection, negotiation procedures, manufacturer reporting requirements, compliance enforcement, and how negotiated Maximum Fair Prices (MFPs) get implemented — starting with the initial price applicability year (IPAY) 2029 [s1]. The practical difference between guidance and regulation matters for durability: formal regulations are harder for a future administration to simply rewrite through internal policy memos, and they go through the notice-and-comment process this proposal is currently in.

The scale the rule would govern

The proposed framework would allow CMS to negotiate prices for up to 20 high-expenditure drugs per year beginning with IPAY 2029 [s1]. That's a ceiling on volume, not a guaranteed number — actual drug selection each year depends on which products meet the program's spending thresholds, and the rule also adds new program-integrity protections and specific provisions addressing small biotech companies, which have raised separate concerns about how negotiation timing interacts with their narrower revenue windows [s1].

Why this is happening now, on this timeline

The negotiation program has already been running: the first set of negotiated prices took effect for ten drugs in 2026, and a third negotiation cycle covering 15 drugs — including, for the first time, drugs covered under Medicare Part B rather than only Part D — is proceeding with prices to take effect in 2028. This proposed rule is separate from those ongoing cycles; it's CMS formalizing the rules that will govern the program going forward, including the cycle after next, rather than changing anything about drugs already selected or already negotiated.

What the public comment period does and doesn't mean

A closed comment period means CMS has received formal input from manufacturers, patient groups, and other stakeholders, not that the rule is finalized. CMS must review submitted comments and can revise the rule in response before issuing a final version — the specifics of drug selection criteria, negotiation procedures, or the small-biotech provisions could all change between this proposed version and whatever CMS ultimately finalizes. The available reporting on the closed comment period doesn't yet indicate a timeline for a final rule.

What to watch next

Whether CMS's final rule preserves the 20-drug-per-year ceiling and the small-biotech provisions in their proposed form, or narrows them in response to comments — and how this permanent framework interacts with drug selections for negotiation cycles beyond the one already underway for 2028 prices, since IPAY 2029 is the first cycle this specific rule would directly govern.